The Metabolic Classroom with Dr. Ben Bikman

Question?
📢 Ask Dr. Bikman’s Digital Mind (multilingual):
https://benbikman.com/ben-bikmans-digital-ai-mind

📢 Dr. Bikman’s Community & Coaching Site: https://insuliniq.com

Summary:
Dr. Bikman explains why some people may produce an inadequate GLP-1 response and how insulin resistance could be part of the problem. Because intestinal L cells have insulin receptors, chronically elevated insulin can make these cells insulin resistant, reducing their ability to release GLP-1 and potentially creating a cycle of faster stomach emptying, higher glucose, more insulin, and further impairment of the natural GLP-1 response.

Ben uses this physiology to explain how he believes GLP-1 medications should be used: not simply to produce maximum weight loss, but as a temporary window in which carbohydrate cravings become easier to control. Rather than escalating automatically to the highest tolerated dose, he favors using the lowest dose that makes refined carbohydrates easier to resist while still requiring the person to exercise some choice and discipline. During that window, the goal is to establish meals centered on protein, healthy fats, and whole foods while improving sleep and resistance training.

Ben also addresses concerns about lean-mass loss, explaining that body-composition scans can classify losses of water, glycogen, organ fat, and even the non-fat portion of adipose tissue as “lean mass.” Ultimately, he argues that GLP-1 therapy should have an exit strategy: improve insulin sensitivity, restore the body's own GLP-1 signaling as much as possible, establish sustainable habits, and then work with a clinician to gradually reduce the medication rather than assuming it must be permanent.

References:
For complete show notes and references, we invite you to become an Insider subscriber. You’ll enjoy real-time, livestream Metabolic Classroom access which includes live Q&A with Ben after the lecture, unlimited access to Dr. Bikman’s Digital Mind, ad-free podcast episodes, show notes and references, and Ben’s Weekly Research Review Podcast. Learn more: https://www.benbikman.com
Hosted on Acast. See acast.com/privacy for more information.

Question?
📢 Ask Dr. Bikman’s Digital Mind (multilingual):
https://benbikman.com/ben-bikmans-digital-ai-mind

📢 Dr. Bikman’s Community & Coaching Site: https://insuliniq.com

Topic:
Continuous glucose monitoring shows how the body handles glucose, but it cannot reveal how much insulin was required to produce that glucose response. By continuously measuring ketones alongside glucose, the new dual sensor may provide an indirect window into insulin activity, fat burning, and metabolic flexibility while also helping people with diabetes detect dangerous ketone elevations earlier.

Summary:
Dr. Ben Bikman explores a new wearable that continuously measures both glucose and ketones. Unlike a traditional continuous glucose monitor, Abbott’s Libre Duo can track beta-hydroxybutyrate (BHB) alongside glucose, providing another window into what is happening metabolically. For people with diabetes, continuous ketone monitoring could provide earlier warning of dangerous ketoacidosis, particularly in people with type 1 diabetes or those using SGLT2 inhibitors.

Ben explains why ketones provide information that glucose alone cannot. Because insulin strongly suppresses fat release, fat oxidation, and ketone production, changes in ketones can serve as an indirect indicator of insulin activity. A seemingly normal glucose response can therefore hide the fact that the body required a large amount of insulin to produce it, while watching glucose and ketones together may reveal more about how readily the body transitions between glucose and fat metabolism.

Ben sees potential value beyond diabetes as well. During fasting or carbohydrate restriction, glucose would generally fall while ketones rise; after a carbohydrate-rich meal, the opposite occurs. Tracking both signals continuously could therefore offer a more complete picture of metabolic flexibility and help people better understand their individual responses to food, fasting, and other metabolic changes.

References:
For complete show notes and references, we invite you to become an Insider subscriber. You’ll enjoy real-time, livestream Metabolic Classroom access which includes live Q&A with Ben after the lecture, unlimited access to Dr. Bikman’s Digital Mind, ad-free podcast episodes, show notes and references, and Ben’s Weekly Research Review Podcast. Learn more: https://www.benbikman.com

Also, Dr. Bikman’s Digital Mind can interact with you in many languages: https://benbikman.com/ben-bikmans-digital-ai-mind

NOTE: The information presented is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Dr. Bikman is not a clinician—and, he is not your doctor. Always seek the advice of your own qualified health providers with questions you may have regarding medical conditions.
Hosted on Acast. See acast.com/privacy for more information.

Question?
📢 Ask Dr. Bikman’s Digital Mind (multilingual):
https://benbikman.com/ben-bikmans-digital-ai-mind

📢 Dr. Bikman’s Community & Coaching Site: https://insuliniq.com

In today’s mini-lecture, Dr. Ben Bikman explains the new generation of oral GLP-1 medications and why two drugs that come as pills can work very differently. Oral semaglutide is still a peptide, so it requires a special absorption enhancer to protect it from digestion and help it cross the stomach lining. Even then, only about 1% of the dose reaches the bloodstream, requiring strict instructions about taking it on an empty stomach. Orforglipron, by contrast, is a small molecule rather than a peptide, allowing it to survive digestion and be absorbed much more efficiently without the same restrictions.

Ben reviews studies comparing the drugs for blood glucose control, weight loss, side effects, and maintaining weight loss after injectable GLP-1 therapy. But he emphasizes that changing the delivery method does not change the underlying metabolic rules: insulin still governs whether fat is stored or released.

Most importantly, Ben argues that GLP-1 medications should be viewed as an opportunity to change metabolic habits rather than simply as long-term weight-loss drugs. Because they can temporarily reduce cravings for sweets and refined carbohydrates, he believes that window should be used to reduce those foods, emphasize protein and fat, and develop habits that can eventually provide an “off-ramp” from the medication..

References:
For complete show notes and references, we invite you to become an Insider subscriber. You’ll enjoy real-time, livestream Metabolic Classroom access which includes live Q&A with Ben after the lecture, unlimited access to Dr. Bikman’s Digital Mind, ad-free podcast episodes, show notes and references, and Ben’s Weekly Research Review Podcast. Learn more: https://www.benbikman.com

NOTE: The information presented is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Dr. Bikman is not a clinician—and, he is not your doctor. Always seek the advice of your own qualified health providers with questions you may have regarding medical conditions.

#GLP1 #GLP1Medications #OralGLP1 #Orforglipron #Semaglutide #WeightLoss #InsulinResistance #Insulin #MetabolicHealth #WeightLossMedication #GLP1WeightLoss #CarbCravings #BloodSugar #Type2Diabetes #Metabolism #LowCarb #DrBenBikman #MetabolicClassroom #MetabolismMatters #HealthScience
Hosted on Acast. See acast.com/privacy for more information.

Question?
📢 Ask Dr. Bikman’s Digital Mind (multilingual):
https://benbikman.com/ben-bikmans-digital-ai-mind

📢 Dr. Bikman’s Community & Coaching Site: https://insuliniq.com

Topic:
Insulin is one of the body’s most important signals for determining whether you burn glucose or fat: when insulin rises, fat release and fat burning fall, while lower insulin allows stored fat to become available for fuel. This helps explain why reducing carbohydrates can dramatically increase fat oxidation even without changing the body’s basic ability to burn fat.

Summary:
In this mini-lecture Ben explains what determines whether the body burns glucose or fat for energy. He begins with the Randle cycle, also called the glucose-fatty acid cycle, which describes how these two fuels compete with one another. But Ben emphasizes that simply having fat available does not mean the body will burn it. Insulin plays a major role in deciding which fuel gets used.

When insulin rises after eating carbohydrates, it suppresses the release of stored fat from fat cells and also makes it harder for long-chain fatty acids to enter the mitochondria to be burned. As a result, the body shifts toward burning glucose. When insulin falls, stored fat becomes available again and can more readily enter the mitochondria for energy.

Ben reviews human studies showing that carbohydrate restriction can dramatically increase fat oxidation, including research in endurance athletes who became highly efficient fat burners without sacrificing performance or muscle glycogen. He also explains what happens with insulin resistance: insulin can remain high enough to block fat burning in muscle while insulin-resistant fat cells continue releasing fatty acids, creating a metabolic mismatch that promotes fat accumulation in places such as the liver and muscle.

The central takeaway is that fuel selection is not simply about calories or which fuel happens to be available. Insulin strongly regulates whether stored fat can be released and burned, which is why lowering carbohydrate intake can dramatically increase the body’s ability to use fat for fuel.

References:
For complete show notes and references, we invite you to become an Insider subscriber. You’ll enjoy real-time, livestream Metabolic Classroom access which includes live Q&A with Ben after the lecture, unlimited access to Dr. Bikman’s Digital Mind, ad-free podcast episodes, show notes and references, and Ben’s Weekly Research Review Podcast. Learn more: https://www.benbikman.com

NOTE: The information presented is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Dr. Bikman is not a clinician—and, he is not your doctor. Always seek the advice of your own qualified health providers with questions you may have regarding medical conditions.
Hosted on Acast. See acast.com/privacy for more information.

Question?
📢 Ask Dr. Bikman’s Digital Mind (multilingual):
https://benbikman.com/ben-bikmans-digital-ai-mind

📢 Dr. Bikman’s Community & Coaching Site: https://insuliniq.com

Topic:
Mitochondria often struggle in insulin resistance not because they are broken, but because there are fewer of them trying to process too much incoming fuel. Exercise and improved metabolic health remain the most effective ways to build healthier mitochondria, while supplements may provide additional—but smaller—benefits.

Summary:
In this mini-lecture, Ben explains why mitochondria have become one of the most talked-about topics in health while separating scientific evidence from popular hype. He begins by reviewing how mitochondria convert the energy stored in carbohydrates, fats, and ketones into ATP, the usable energy that powers virtually every function in the body. Along the way, he explains concepts such as glycolysis, the Krebs cycle, the electron transport system, coupling versus uncoupling, and the production of reactive oxygen species.

Ben then examines what happens in insulin resistance and type 2 diabetes. Rather than concluding that mitochondria are "broken," he explains that the evidence points to a different problem: people with insulin resistance generally have fewer mitochondria, more fragmented mitochondrial networks, and an excessive fuel load. As glucose and fatty acids arrive faster than the mitochondria can process them, byproducts such as lactate and acylcarnitines begin to accumulate, signaling a mismatch between fuel supply and mitochondrial capacity.

The lecture also reviews current approaches to measuring mitochondrial health, including fasting lactate, the lactate-to-pyruvate ratio, and newer biomarkers such as GDF15 and FGF21. Dr. Bikman discusses several popular mitochondrial interventions—including methylene blue, urolithin A, CoQ10, red-light therapy, and cold exposure—highlighting where human evidence is promising and where it remains limited.

The central message is that no supplement outperforms the fundamentals. Exercise consistently increases mitochondrial number and function while improving insulin sensitivity, and lowering carbohydrate intake reduces the fuel burden placed on mitochondria. Together, these strategies address the root problem more effectively than relying on supplements alone.

References:
For complete show notes and references, we invite you to become an Insider subscriber. You’ll enjoy real-time, livestream Metabolic Classroom access which includes live Q&A with Ben after the lecture, unlimited access to Dr. Bikman’s Digital Mind, ad-free podcast episodes, show notes and references, and Ben’s Weekly Research Review Podcast. Learn more: https://www.benbikman.com

NOTE: The information presented is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Dr. Bikman is not a clinician—and, he is not your doctor. Always seek the advice of your own qualified health providers with questions you may have regarding medical conditions.

#Mitochondria #MitochondrialHealth #InsulinResistance #MetabolicHealth #ExerciseScience #ATP #CellBiology #Type2Diabetes #OxidativeStress #Lactate #Ketones #CoQ10 #UrolithinA #RedLightTherapy #ColdExposure #DrBenBikman #MetabolicClassroom #Metabolism #HealthScience #LowCarbScience
Hosted on Acast. See acast.com/privacy for more information.